Arena Pharmaceuticals Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Employees
-
448
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.7B
Arena Pharmaceuticals General Information
Description
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Contact Information
Website
www.arenapharm.comCorporate Office
- 6154 Nancy Ridge Drive
- San Diego, CA 92121
- United States
Corporate Office
- 6154 Nancy Ridge Drive
- San Diego, CA 92121
- United States
Arena Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 11-Mar-2022 | $6.7B | Completed | Generating Revenue | ||
| 9. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 8. Secondary Transaction - Open Market | Completed | Profitable | ||||
| 7. PIPE | 01-May-2012 | Completed | Profitable | |||
| 6. PIPE | 29-Mar-2011 | Completed | Profitable | |||
| 5. General Corporate Purpose | 17-Jun-2009 | Completed | Profitable | |||
| 4. PIPE | 24-Dec-2003 | Completed | Profitable | |||
| 3. IPO | 28-Jul-2000 | Completed | Profitable | |||
| 2. Grant | 19-Jan-2000 | $106K | $17M | Completed | Startup | |
| 1. Later Stage VC (Series D) | 22-Feb-1999 | $17M | $17M | Completed | Startup |
Arena Pharmaceuticals Comparisons
Industry
Financing
Details
Arena Pharmaceuticals Competitors (34)
One of Arena Pharmaceuticals’s 34 competitors is Takeda Pharmaceutical, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical | Corporation | Tokyo, Japan | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Neuro-Sys | Accelerator/Incubator Backed | Gardanne, France | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Mesoblast | Corporation | Melbourne, Australia |
Arena Pharmaceuticals Patents
Arena Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260091039-A1 | Hydrochloric acid salt of a 5-ht2c agonist | Pending | 01-Oct-2024 | ||
| WO-2026075995-A1 | Hydrochloric acid salt of a 5-ht2c agonist | Pending | 01-Oct-2024 | ||
| WO-2026043678-A1 | Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy | Pending | 23-Aug-2024 | ||
| WO-2026025075-A1 | Bexicaserin for use in the treatment and/or prevention of epileptic disorders in a child patient | Pending | 26-Jul-2024 | ||
| US-20260048069-A1 | Methods of treatment | Pending | 26-Jul-2024 | A61K31/5517 |
Arena Pharmaceuticals Signals
Arena Pharmaceuticals Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Certara | Corporation | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Eaton Vance | Asset Manager | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| Great Point Partners | PE/Buyout | Minority |
Arena Pharmaceuticals Investments & Acquisitions (5)
Arena Pharmaceuticals’s most recent deal was a Grant with Coral Genomics for . The deal was made on 01-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Coral Genomics | 01-Sep-2021 | Grant | Biotechnology | ||
| Longboard Pharmaceuticals | 28-Oct-2020 | Early Stage VC | Drug Discovery | ||
| Siegfried Holding (Pharmaceutical Final Dosage Forms Business) | 09-Jan-2008 | Merger/Acquisition | Pharmaceuticals | ||
| TaiGen Biotechnology | 01-Jul-2001 | Early Stage VC | Drug Discovery | ||
| Bunsen Rush Laboratories | 01-Feb-2001 | Merger/Acquisition | Discovery Tools (Healthcare) |
Arena Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
15.64 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Arena Pharmaceuticals FAQs
-
When was Arena Pharmaceuticals founded?
Arena Pharmaceuticals was founded in 1997.
-
Where is Arena Pharmaceuticals headquartered?
Arena Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Arena Pharmaceuticals?
Arena Pharmaceuticals has 448 total employees.
-
What industry is Arena Pharmaceuticals in?
Arena Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Arena Pharmaceuticals a private or public company?
Arena Pharmaceuticals is a Private company.
-
What is the current valuation of Arena Pharmaceuticals?
The current valuation of Arena Pharmaceuticals is .
-
What is Arena Pharmaceuticals’s current revenue?
The current revenue for Arena Pharmaceuticals is .
-
How much funding has Arena Pharmaceuticals raised over time?
Arena Pharmaceuticals has raised $366M.
-
Who are Arena Pharmaceuticals’s investors?
Certara, Deerfield Management, Eaton Vance, Frazier Healthcare Partners, and Great Point Partners are 5 of 11 investors who have invested in Arena Pharmaceuticals.
-
Who are Arena Pharmaceuticals’s competitors?
Takeda Pharmaceutical, Gilead, Neuro-Sys, Bristol-Myers Squibb, and Mesoblast are some of the 34 competitors of Arena Pharmaceuticals.
-
When was Arena Pharmaceuticals acquired?
Arena Pharmaceuticals was acquired on 11-Mar-2022.
-
Who acquired Arena Pharmaceuticals?
Arena Pharmaceuticals was acquired by Pfizer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process